RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.


RTI International Makes Strategic Investment in BioIQ

The relationship will further BioIQ’s health plan member engagement outcomes and both organizations’ objectives to improve the human condition.

RESEARCH TRIANGLE PARK, N.C. —  BioIQ, a healthcare engagement and gap closure company, today announced that RTI International, a leading global research institute, is participating in a round of financing joined by existing investors Savitr Capital, HealthQuest Capital and Arboretum Ventures. The $14 million financing comes on the heels of BioIQ reaching a major milestone on its journey to positively impact 100 million patient lives — its one millionth colorectal cancer (CRC) screening.

Funding will support BioIQ’s continued growth, expanding technology platform, and its mission to help transform the U.S. healthcare system. As part of the relationship, RTI and BioIQ have the opportunity to align on initiatives to analyze the most effective avenues for engaging patients and closing care gaps at scale, outcomes that impact BioIQ’s growing stable of national and regional health plan clients. Insights will be gleaned from BioIQ’s unique knowledge of how members use and navigate emerging home and retail care delivery models to further best practices in healthcare quality and care gap closure. Leveraging AI and technology, BioIQ uses these insights to configure care at a personal level for an entire population, driving both clinical adherence and patient satisfaction.

“RTI’s depth of scientific expertise and understanding of high-growth healthcare companies aligns perfectly with our mission to leverage insights on human behavior to help people understand their health risks and connect to personalized interventions,” said Justin Bellante, CEO of BioIQ. "RTI is a great partner to help us advance how we can improve the health and lives of people every day.”

“We are delighted to join the existing investors and help support the executive team of BioIQ as they advance their mission,” said Matt Jenkins, vice president and head of corporate development at RTI. "BioIQ’s approach to driving adoption of important testing and screenings by leveraging analytics and emerging consumer insights is well aligned with our focus on helping to improve population health through science driven solutions.”